Last updated: February 10, 2026
What is the case about?
Hikma Pharmaceuticals USA Inc. filed a patent infringement lawsuit against Aurobindo Pharma Limited on February 4, 2021, in the U.S. District Court for the District of New Jersey. The core issue involves allegations that Aurobindo’s generic versions of Hikma’s branded drug infringe on U.S. Patent No. 10,799,802, relating to a specific formulation of a major pharmaceutical ingredient.
What patents are at stake?
Hikma asserts U.S. Patent No. 10,799,802. The patent issued on October 13, 2020. It covers a pharmaceutical formulation targeting a therapeutically effective dose with certain excipients that enhance bioavailability. The patent claims a specific combination used in a drug delivery system.
Key claims specify a controlled-release oral dosage form containing a particular ratio of active pharmaceutical ingredient (API) and excipients configured for sustained release. The patent's expiration date is set for September 2038.
Who are the parties involved?
- Plaintiff: Hikma Pharmaceuticals USA Inc., a subsidiary of Hikma Pharmaceuticals PLC, a multinational pharmaceutical company based in Jordan.
- Defendant: Aurobindo Pharma Limited, an India-based generic drug manufacturer with U.S. operations, known for producing generic formulations across a range of therapeutic areas.
What are the key allegations?
Hikma claims Aurobindo’s generic formulations of the drug infringe its ‘802 patent through both literal infringement and the doctrine of equivalents. The allegations include:
- Aurobindo's filing of abbreviated new drug applications (ANDAs) to market generic versions.
- Submission of Paragraph IV certifications asserting non-infringement or invalidity of Hikma’s patent, triggering 30-month stay provisions under the Hatch-Waxman Act.
- Aurobindo’s marketing preparations prior to patent expiry.
Hikma seeks injunctive relief to prevent the launch of generic products, monetary damages for infringement, and attorney's fees.
What are the procedural developments so far?
The case was filed in February 2021. Hikma filed an emergency motion for a preliminary injunction in August 2021, seeking to prevent Aurobindo from marketing its generic versions pending trial. The court held a hearing on September 2021. The case remains active, with scheduling orders in place for discovery, expert reports, and trial.
What are the strategic implications?
- Patent enforcement: Hikma actively defends its patent rights, aligning with scalable patent strategies in the biosimilar and generic markets.
- Generics entry: Aurobindo’s willingness to challenge patents through Paragraph IV filings reflects its strategy to gain rapid market entry.
- Market impact: Successful infringement defense could delay Aurobindo’s entry, preserving Hikma’s market share and pricing power.
What are broader market implications?
This litigation exemplifies the ongoing patent disputes in the U.S. generic drug industry. It highlights the strategic use of Paragraph IV certifications and the potential for protracted legal battles that influence market dynamics and pricing strategies.
What are the potential outcomes?
- Infringement found: Court issues an injunction blocking Aurobindo’s generic product launch, maintaining exclusivity for Hikma until patent expiration.
- Invalidity ruling: Patent invalidated, allowing Aurobindo to enter market while Hikma seeks appeal.
- Settlement: Parties settle confidentially, possibly involving license agreements or patent licensing.
Key Takeaways
- Hikma’s patent infringement suit against Aurobindo centers on a controlled-release pharmaceutical formulation.
- The case impacts market entry timelines for generic versions of the drug, with potential delays depending on rulings.
- The dispute underscores strategic patent enforcement in the highly competitive generic drug landscape.
- The outcome will influence Aurobindo’s market access and Hikma’s patent protections.
- Ongoing litigation may involve settlement or continued legal challenges related to patent validity.
FAQs
What specific formulation does Hikma’s patent protect?
It covers a controlled-release oral dosage form with particular ratios of API and excipients designed for sustained drug release, optimized for bioavailability.
When is the next major court deadline?
The case is scheduled for a trial in mid-2023, with pre-trial motions expected in early 2023.
Has Aurobindo launched its generic version?
As of now, Aurobindo has not launched its generic version due to the ongoing litigation and FDA review process.
Could the case set a precedent for other generic patent challenges?
Yes. Successful enforcement in this case could strengthen patent holders’ confidence in defending formulation patents, influencing future Paragraph IV litigations.
What is the potential financial impact?
If Hikma prevails, it could receive significant damages, and Aurobindo could be barred from market entry, affecting the competitive landscape.
References
- U.S. District Court Docket for Hikma Pharmaceuticals USA Inc. v. Aurobindo Pharma Limited, Case No. 1:21-cv-00228, filed February 2021.
- U.S. Patent No. 10,799,802.
- FDA Regulation and Paragraph IV Certification procedures.
- Industry reports on patent litigation trends in the generic pharmaceutical industry.
Note: This summary provides an overview based on publicly available information and legal filings. Ongoing developments should be monitored for updates.
